ArticleFrontiers in oncology2026
MRI-based habitat radiomics analysis for predicting clinically significant prostate cancer: a retrospective dual-center study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the performance of habitat radiomics based on multi-parameter magnetic resonance (mpMRI) in predicting clinically significant prostate cancer (csPCa). Materials and methods: This retrospective study included 642 patients with pathology-proven prostate cancer (PCa) and benign prostatic hyperplasia (BPH) from two institutions. Center 1 was split into a training and internal test set, while Center 2 served as the external test set. Tumor regions of interest (ROI) were divided into three spatial habitats by K-means clustering. The classical radiomics score (Crad-score) and habitat radiomics score (Hrad-score) were developed following feature selection and dimensionality reduction. Multivariable analysis was conducted to ascertain independent predictors. The performance of these models was evaluated using receiver operating characteristic (ROC) curves. The Delong test was used to compare the area under the curves(AUCs) between models. The best-performing radiomics model was integrated with clinical data to develop a combined model, presented as a nomogram. Moreover, we further investigated whether the combined model provided additional value for improving the predictive accuracy of csPCa detection in PI-RADS 3-4 lesions. Results: The Hrad-score showed better performance than the Crad-score, achieving AUCs of 0.931, 0.907, and 0.893 in the training, internal test, and external test sets, respectively. The CH Combined model yielded optimal performance in all three sets, with AUCs of 0.966, 0.954, and 0.954, respectively. Additionally, in the subgroup of patients with PI-RADS 3-4 lesions, the CH combined model outperformed other single models in predicting csPCa, with AUCs of 0.933, 0.869 and 0.962 across the three sets. Conclusion: Habitat analysis could act as a non-invasive auxiliary tool for predicting csPCa, and furthermore, it could reduce unnecessary biopsies and assist physicians in making clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.